|
1
|
Lu KH and Broaddus RR: Endometrial Cancer.
N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Njoku K, Abiola J, Russell J and Crosbie
EJ: Endometrial cancer prevention in high-risk women. Best Pract
Res Clin Obstet Gynaecol. 65:66–78. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aoki Y, Kanao H, Wang X, Yunokawa M,
Omatsu K, Fusegi A and Takeshima N: Adjuvant treatment of
endometrial cancer today. Jpn J Clin Oncol. 50:753–765. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Habibi Jouybari M, Hosseini S, Mahboobnia
K, Boloursaz LA, Moradi M and Irani M: Simultaneous controlled
release of 5-FU, DOX and PTX from
chitosan/PLA/5-FU/g-C3N4-DOX/g-C3N4-PTX triaxial nanofibers for
breast cancer treatment in vitro. Colloids Surf B Biointerfaces.
179:495–504. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou X, Cao C, Li N and Yuan S: SYL3C
aptamer-anchored microemulsion co-loading β-elemene and PTX
enhances the treatment of colorectal cancer. Drug Deliv.
26:886–897. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ebeid K, Meng X, Thiel KW, Do AV, Geary
SM, Morris AS, Pham EL, Wongrakpanich A, Chhonker YS, Murry DJ, et
al: Synthetically lethal nanoparticles for treatment of endometrial
cancer. Nat Nanotechnol. 13:72–81. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dinkic C, Kruse A, Zygmunt M, Schuetz F,
Brucker J, Rom J, Sohn C and Fluhr H: Influence of Paclitaxel and
Heparin on Vitality, Proliferation and Cytokine Production of
Endometrial Cancer Cells. Geburtshilfe Frauenheilkd. 77:1104–1110.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Q, Liu F, Wang B, Li Z, Zhou D, Yang
Q, Dong J and Li J: HER-2 expression in biopsy and surgical
specimen on prognosis of osteosarcoma: A systematic review and
meta-analysis of 16 studies. Medicine (Baltimore). 95:e36612016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Press MF, Cordon-Cardo C and Slamon DJ:
Expression of the HER-2/neu proto-oncogene in normal human adult
and fetal tissues. Oncogene. 5:953–962. 1990.PubMed/NCBI
|
|
10
|
Mori S, Akiyama T, Yamada Y, Morishita Y,
Sugawara I, Toyoshima K and Yamamoto T: C-erbB-2 gene product, a
membrane protein commonly expressed on human fetal epithelial
cells. Lab Invest. 61:93–97. 1989.PubMed/NCBI
|
|
11
|
Hua S, Chuanbo F, Zhonglin W, Shuangjiu Z
and Xinwen Z: The expression and prognostic significance of Topo-II
and c-erbB-2 in breast cancer. Minerva Med. Jul 17–2020.(Epub ahead
of print). doi: 10.23736/S0026-4806.20.06637-9. PubMed/NCBI
|
|
12
|
Wang K, Liu J, Duan Y, Wu J, Dongye S,
Wang Y, Liu Z and Han G: C-erbB-2 expression is related with
pathological progression of gastric cancer: Results of a
non-radioactive in situ hybridization. Int J Clin Exp Pathol.
10:9649–9653. 2017.PubMed/NCBI
|
|
13
|
Canoz O, Ozkan M, Arsav V, Er O, Coskun
HS, Soyuer S and Altinbas M: The role of c-erbB-2 expression on the
survival of patients with small-cell lung cancer. Lung.
184:267–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao W, Dong X, Zhao H, Han S, Nie R,
Zhang X and An R: Expression of MIF and c-erbB-2 in endometrial
cancer. Mol Med Rep. 13:3828–3834. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Q, Hou CN, Yang HJ, He Z and Zuo MZ:
Distinct expression and prognostic value of members of the
epidermal growth factor receptor family in ovarian cancer. Cancer
Manag Res. 10:6937–6948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li BT, Ross DS, Aisner DL, Chaft JE, Hsu
M, Kako SL, Kris MG, Varella-Garcia M and Arcila ME: HER2
Amplification and HER2 Mutation Are Distinct Molecular Targets in
Lung Cancers. J Thorac Oncol. 11:414–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Erickson BK, Zeybek B, Santin AD and Fader
AN: Targeting human epidermal growth factor receptor 2 (HER2) in
gynecologic malignancies. Curr Opin Obstet Gynecol. 32:57–64. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho S, Shin J and Cho BK: Applications of
CRISPR/Cas System to Bacterial Metabolic Engineering. Int J Mol
Sci. 19:10892018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishino Y, Shinagawa H, Makino K, Amemura M
and Nakata A: Nucleotide sequence of the iap gene, responsible for
alkaline phosphatase isozyme conversion in Escherichia coli,
and identification of the gene product. J Bacteriol. 169:5429–5433.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hryhorowicz M, Lipiński D, Zeyland J and
Słomski R: CRISPR/Cas9 Immune System as a Tool for Genome
Engineering. Arch Immunol Ther Exp (Warsz). 65:233–240. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhan T, Rindtorff N, Betge J, Ebert MP and
Boutros M: CRISPR/Cas9 for cancer research and therapy. Semin
Cancer Biol. 55:106–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gupta D, Bhattacharjee O, Mandal D, Sen
MK, Dey D, Dasgupta A, Kazi TA, Gupta R, Sinharoy S, Acharya K, et
al: CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life
Sci. 232:1166362019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu C, Zhang L, Liu H and Cheng K:
Delivery strategies of the CRISPR-Cas9 gene-editing system for
therapeutic applications. J Control Release. 266:17–26. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang F, Li Y, Liufu C, Wang Y and Chen Z:
Preparation of Cationic Lipid-coated Ultrasound Contrast Agents and
Noninvasive Gene Transfection Via Ultrasound-targeted Microbubble
Destruction. Curr Pharm Des. 24:3587–3595. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Delalande A, Bastié C, Pigeon L, Manta S,
Lebertre M, Mignet N, Midoux P and Pichon C: Cationic gas-filled
microbubbles for ultrasound-based nucleic acids delivery. Biosci
Rep. 37:BSR201606192017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou Q, Deng Q, Hu B, Wang YJ, Chen JL,
Cui JJ, Cao S and Song HN: Ultrasound combined with targeted
cationic microbubble-mediated angiogenesis gene transfection
improves ischemic heart function. Exp Ther Med. 13:2293–2303. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manta S, Renault G, Delalande A, Couture
O, Lagoutte I, Seguin J, Lager F, Houzé P, Midoux P, Bessodes M, et
al: Cationic microbubbles and antibiotic-free miniplasmid for
sustained ultrasound-mediated transgene expression in liver. J
Control Release. 262:170–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu X, Wan T, Xin H, Li D, Pan H, Wu J and
Ping Y: Delivery of CRISPR/Cas9 for therapeutic genome editing. J
Gene Med. 21:e31072019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lino CA, Harper JC, Carney JP and Timlin
JA: Delivering CRISPR: A review of the challenges and approaches.
Drug Deliv. 25:1234–1257. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen M, Mao A, Xu M, Weng Q, Mao J and Ji
J: CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Cancer Lett. 447:48–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yip BH: Recent Advances in CRISPR/Cas9
Delivery Strategies. Biomolecules. 10:8392020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Li X, Liu L, Liu B, Wang F and
Chen C: Tissue Targeting and Ultrasound-Targeted Microbubble
Destruction Delivery of Plasmid DNA and Transfection In Vitro. Cell
Mol Bioeng. 13:99–112. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kooiman K, Roovers S, Langeveld SAG,
Kleven RT, Dewitte H, O'Reilly MA, Escoffre JM, Bouakaz A, Verweij
MD, Hynynen K, et al: Ultrasound-Responsive Cavitation Nuclei for
Therapy and Drug Delivery. Ultrasound Med Biol. 46:1296–1325. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu X, Guo J, He C, Geng H, Yu G, Li J,
Zheng H, Ji X and Yan F: Ultrasound triggered image-guided drug
delivery to inhibit vascular reconstruction via paclitaxel-loaded
microbubbles. Sci Rep. 6:216832016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang D, Yang L, Tian H, Fu B, Chen W, Liu
K, Jia Z, Jiang S, Han X and Sun L: [Enhancement of gene
transfection efficiency and therapeutic effect of
ultrasound-targeted microbubble destruction in vivo with cationic
microbubble]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 32:228–236.
2018.(In Chinese). PubMed/NCBI
|
|
37
|
Du M, Chen Z, Chen Y and Li Y:
Ultrasound-Targeted Delivery Technology: A Novel Strategy for
Tumor- Targeted Therapy. Curr Drug Targets. 20:220–231. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Leon A, Perera R, Nittayacharn P,
Cooley M, Jung O and Exner AA: Ultrasound Contrast Agents and
Delivery Systems in Cancer Detection and Therapy. Adv Cancer Res.
139:57–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Endo-Takahashi Y and Negishi Y:
Microbubbles and Nanobubbles with Ultrasound for Systemic Gene
Delivery. Pharmaceutics. 12:9642020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qian L, Thapa B, Hong J, Zhang Y, Zhu M,
Chu M, Yao J and Xu D: The present and future role of ultrasound
targeted microbubble destruction in preclinical studies of cardiac
gene therapy. J Thorac Dis. 10:1099–1111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Szablowski JO, Bar-Zion A and Shapiro MG:
Achieving Spatial and Molecular Specificity with
Ultrasound-Targeted Biomolecular Nanotherapeutics. Acc Chem Res.
52:2427–2434. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou LQ, Li P, Cui XW and Dietrich CF:
Ultrasound nanotheranostics in fighting cancer: Advances and
prospects. Cancer Lett. 470:204–219. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu J, Chen J, Feng Y, Zhang S, Lin L, Guo
Z, Sun P, Xu C, Tian H and Chen X: An immune cocktail therapy to
realize multiple boosting of the cancer-immunity cycle by
combination of drug/gene delivery nanoparticles. Sci Adv.
6:eabc78282020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu P, Liu X, Cheng Y, Zhong S, Shi X,
Wang S, Liu M, Ding J and Zhou W: Core-Shell Nanosystems for
Self-Activated Drug-Gene Combinations against Triple-Negative
Breast Cancer. ACS Appl Mater Interfaces. 12:53654–53664. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han H, Kim D, Jang Y, Seo M, Kim K, Lee JB
and Kim H: Focused ultrasound-triggered chemo-gene therapy with
multifunctional nanocomplex for enhancing therapeutic efficacy. J
Control Release. 322:346–356. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou X, Yang Y, Ma P, Wang N, Yang D, Tu
Q, Sun B, Xiang T, Zhao X, Hou Z, et al: TRIM44 is indispensable
for glioma cell proliferation and cell cycle progression through
AKT/p21/p27 signaling pathway. J Neurooncol. 145:211–222. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shamloo B and Usluer S: p21 in Cancer
Research. Cancers (Basel). 11:11782019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rodriguez-Cupello C, Dam M, Serini L, Wang
S, Lindgren D, Englund E, Kjellman P, Axelson H, García-Mariscal A
and Madsen CD: The STRIPAK Complex Regulates Response to
Chemotherapy Through p21 and p27. Front Cell Dev Biol. 8:1462020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang Y, Wang W, Chen Y, Huang Y, Zhang J,
He S, Tan Y, Qiang F, Li A, Røe OD, et al: The opposite prognostic
significance of nuclear and cytoplasmic p21 expression in
resectable gastric cancer patients. J Gastroenterol. 49:1441–1452.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Razavipour SF, Harikumar KB and
Slingerland JM: p27 as a Transcriptional Regulator: New Roles in
Development and Cancer. Cancer Res. 80:3451–3458. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lu P, Redd Bowman KE, Brown SM,
Joklik-Mcleod M, Vander Mause ER, Nguyen HTN and Lim CS: p53-Bad: A
Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the
Mitochondria for Ovarian Cancer Gene Therapy. Mol Pharm.
16:3386–3398. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Murugan AK: mTOR: Role in cancer,
metastasis and drug resistance. Semin Cancer Biol. 59:92–111. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hua H, Kong Q, Zhang H, Wang J, Luo T and
Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol.
12:712019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Magaway C, Kim E and Jacinto E: Targeting
mTOR and Metabolism in Cancer: Lessons and Innovations. Cells.
8:15842019. View Article : Google Scholar : PubMed/NCBI
|
